Inter city tales - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Inter city tales

Pharmaceutical Technology Europe
Volume 23, Issue 5

Rich Whitworth
As I strolled through Times Square, famous brand coffee cup in hand, towards the Jacob K. Javits Convention Center in New York, my thoughts were entirely focused on Interphex. As I sit here, typing this, I realise that the Interpack event in Dusseldorf looms large. And I am constantly aware of the fact that we are interconnected at all times thanks to the interweb (as my father says). "Inter" has become an important word for us, but what does it mean?

Well, turns out it's all about sharing.

At Interphex, so much valuable information and intelligence was divulged to expectant delegates. One particular stand out for me was a unified message from not one but two officials that the FDA fully supports continuous manufacturing. Watch this space for forthcoming articles on this very topic. It seems that 'missing out' on this sort of information is what drives our thirst to visit such exhibitions, make new contacts and join salient groups on LinkedIn (other networking tools are available!).

What can be shared and, thus, what can be learned?

No doubt Interpack will provide enormous amounts of potential in this vein, spanning multiple industries as it does. I hope to share the experience with some of our readers—you know who you are!

Here at Pharmaceutical Technology Europe, sharing is becoming more and more important for us. Peer reviews are a staple of our publication and within these covers you will find three such articles, all delivering strong insight on diverse topics. This has only been made possible by working more closely with Pharmaceutical Technology in North America. And I would like to take this opportunity to thank them for their continued support and ethic of sharing.

What this means to you, dear reader, is that our scope for sharing industry knowledge has widened significantly. All peer reviewed articles will now be published simultaneously in both PTE and PT — especially great if you happen to be the author. Our hope is that this move will aid the pharma industry by connecting you, the people in that industry, to what's happening on a scientific level around the world.

Please feel free to share your thoughts directly with me at
or with other likeminded readers on LinkedIn (

Best wishes,
Rich Whitworth, Editor


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology Europe,
Click here